Puretech Health (LON:PRTC) had its price target raised by Numis Securities from GBX 207 ($2.77) to GBX 233 ($3.12) in a research note released on Thursday. They currently have a buy rating on the stock.
Other equities research analysts have also issued research reports about the stock. N+1 Singer reissued a buy rating on shares of Puretech Health in a report on Thursday. Peel Hunt reissued a buy rating and issued a GBX 278 ($3.72) price target on shares of Puretech Health in a report on Thursday. Jefferies Group reaffirmed a buy rating on shares of Puretech Health in a report on Friday, November 17th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 248 ($3.32) target price on shares of Puretech Health in a report on Monday, September 25th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of GBX 248 ($3.32).
Shares of Puretech Health (LON PRTC) opened at GBX 127 ($1.70) on Thursday. Puretech Health has a 1-year low of GBX 110 ($1.47) and a 1-year high of GBX 139 ($1.86).
About Puretech Health
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
What are top analysts saying about Puretech Health PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puretech Health PLC and related companies.